Showing results (411-420 of 439) with videos related to

Sort By:
Pageof 44
Neurology|June 9, 2017
Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB ConsortiumIan G McKeith, Bradley F Boeve, Dennis W Dickson, et al.
Neurology|September 25, 2024
Gene-Specific Effects on Brain Volume and Cognition of TMEM106B in Frontotemporal Lobar DegenerationMarijne Vandebergh, Eliana Marisa Ramos, Nick Corriveau-Lecavalier, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|January 14, 2026
Alzheimer's disease polygenic risk in early- and late-onset Alzheimer's diseaseJulian V Pentchev, Trever Jackson, Naazneen Khan, et al.
Neurobiology of Aging|September 27, 2016
Analysis of C9orf72 repeat expansions in a large international cohort of dementia with Lewy bodiesCelia Kun-Rodrigues, Owen A Ross, Tatiana Orme, et al.
The Lancet. Neurology|December 22, 2017
Investigating the genetic architecture of dementia with Lewy bodies: a two-stage genome-wide association studyRita Guerreiro, Owen A Ross, Celia Kun-Rodrigues, et al.
Neurobiology of Aging|November 19, 2018
A comprehensive screening of copy number variability in dementia with Lewy bodiesCelia Kun-Rodrigues, Tatiana Orme, Susana Carmona, et al.
The Lancet. Neurology|March 22, 2025
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trialRandall J Bateman, Yan Li, Eric M McDade, et al.
Neurobiology of Disease|April 7, 2019
Heritability and genetic variance of dementia with Lewy bodiesRita Guerreiro, Valentina Escott-Price, Dena G Hernandez, et al.
Nature Medicine|June 22, 2021
A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's diseaseStephen Salloway, Martin Farlow, Eric McDade, et al.
Medrxiv : the Preprint Server for Health Sciences|February 20, 2025
Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU TrialRandall J Bateman, Yan Li, Eric M McDade, et al.
Pageof 44